Table 2

Clinical data before (baseline) and after (treatment) 13 weeks of randomized treatment

VariableCBD (n = 13)THCV (n = 12)1:1 CBD/THCV (n = 11)20:1 CBD/THCV (n = 12)Placebo (n = 14)
BaselineTreatmentBaselineTreatmentBaselineTreatmentBaselineTreatmentBaselineTreatment
HDL-C (mmol/L)1.0 ± 0.31.0 ± 0.31.1 ± 0.11.1 ± 0.21.0 ± 0.21.0 ± 0.31.0 ± 0.11.0 ± 0.11.0 ± 0.31.0 ± 0.2
Total-C (mmol/L)4.5 ± 0.94.3 ± 0.73.8 ± 0.93.7 ± 1.04.2 ± 1.13.8 ± 0.74.6 ± 0.94.2 ± 0.64.0 ± 0.73.9 ± 0.9
LDL-C (mmol/L)2.5 ± 0.72.4 ± 0.62.0 ± 0.62.0 ± 0.82.2 ± 0.82.0 ± 0.52.8 ± 0.62.5 ± 0.52.2 ± 0.62.2 ± 0.7
HDL/LDL-C ratio0.5 ± 0.20.4 ± 0.20.6 ± 0.30.6 ± 0.30.5 ± 0.20.6 ± 0.20.4 ± 0.10.4 ± 0.10.5 ± 0.10.5 ± 0.1
UC VLDL-C (mmol/L)0.8 ± 0.41.0 ± 0.51.0 ± 0.70.9 ± 0.71.0 ± 0.51.0 ± 0.41.1 ± 0.41.0 ± 0.31.0 ± 0.50.9 ± 0.4
TG (mmol/L)2.2 ± 1.42.3 ± 1.31.7 ± 1.11.8 ± 1.52.4 ± 1.62.2 ± 1.21.9 ± 0.71.9 ± 0.72.1 ± 1.42.0 ± 1.1
Apo A (μmol/L)48.6 ± 9.743.6 ± 6.648.5 ± 7.049.1 ± 6.4b48.7 ± 11.146.8 ± 7.448.7 ± 10.045.7 ± 6.347.3 ± 8.843.9 ± 7.2
Apo B (μmol/L)3.1 ± 0.83.3 ± 0.72.6 ± 0.62.7 ± 1.03.0 ± 0.92.9 ± 0.73.4 ± 0.73.4 ± 0.62.9 ± 0.73.0 ± 0.6
Apo B/Apo A ratio0.6 ± 0.20.7 ± 0.20.5 ± 0.10.5 ± 0.2a0.6 ± 0.20.6 ± 0.20.7 ± 0.20.7 ± 0.10.6 ± 0.20.7 ± 0.1
NEFA (mmol/L)0.6 ± 0.20.5 ± 0.30.6 ± 0.10.6 ± 0.20.7 ± 0.30.6 ± 0.20.7 ± 0.20.6 ± 0.20.6 ± 0.20.6 ± 0.2
Liver TG (%)26.9 ± 16.922.2 ± 17.111.9 ± 8.011.5 ± 13.533.3 ± 18.332.2 ± 26.223.2 ± 14.325.4 ± 17.420.5 ± 15.118.5 ± 15.4
Fasting glucose (mmol/L)8.0 ± 2.38.4 ± 2.87.4 ± 2.36.7 ± 1.9b8.5 ± 2.58.7 ± 2.08.4 ± 2.88.8 ± 3.17.6 ± 1.48.0 ± 1.6
Fructosamine (µmol/L)259.5 ± 34.4256.8 ± 44.6238.2 ± 25.0239.3 ± 28.7254.4 ± 35.7256.0 ± 55.2253.3 ± 34.8268.8 ± 58.2241.4 ± 19.3253.7 ± 32.0
HbA1c (%)6.9 ± 0.97.0 ± 1.16.6 ± 0.66.5 ± 0.77.2 ± 1.17.4 ± 1.57.2 ± 0.97.3 ± 1.37.0 ± 0.77.3 ± 1.0
Glucose, 2-h OGTT (mmol/L)7.4 ± 2.46.6 ± 2.75.7 ± 3.16.2 ± 2.78.7 ± 3.88.8 ± 2.55.6 ± 3.46.6 ± 2.37.9 ± 2.68.4 ± 2.2
Insulin, 2-h OGTT (pmol/L)604.1 ± 605.2454.8 ± 387.5661.0 ± 381.2724.9 ± 589.6789.5 ± 677.2900.2 ± 875.8659.3 ± 570.4651.6 ± 730.0653.6 ± 381.5619.7 ± 455.3
Fasting insulin (pmol/L)110.3 ± 42.8123.8 ± 60.8152.9 ± 94.2203.5 ± 197.7175.3 ± 86.1185.7 ± 67.6197.6 ± 107.9192.2 ± 69.1171.7 ± 105.0179.7 ± 75.7
C-peptide (nmol/L)0.9 ± 0.20.9 ± 0.21.0 ± 0.31.1 ± 0.51.2 ± 0.21.2 ± 0.31.1 ± 0.31.2 ± 0.31.0 ± 0.41.1 ± 0.4
HOMA2-IR2.3 ± 0.92.6 ± 1.53.0 ± 1.93.8 ± 3.33.5 ± 1.63.7 ± 1.34.2 ± 2.94.0 ± 1.53.4 ± 2.13.6 ± 1.5
HOMA2 insulin sensitivity51.3 ± 20.153.0 ± 36.247.3 ± 32.453.5 ± 44.334.9 ± 17.130.4 ± 12.930.2 ± 11.428.9 ± 11.542.4 ± 29.237.8 ± 32.2
HOMA2 β-cell function70.9 ± 27.269.6 ± 31.5105.1 ± 64.7144.4 ± 110.3b95.7 ± 50.793.8 ± 47.5103.7 ± 60.697.9 ± 50.596.4 ± 41.494.7 ± 39.2
BMI (kg/m2)33.2 ± 5.433.0 ± 4.934.0 ± 6.533.8 ± 6.736.4 ± 5.636.1 ± 5.735.4 ± 4.635.4 ± 4.433.4 ± 7.032.9 ± 7.7
Waist circumference (cm)107.7 ± 10.8108.0 ± 10.6115.3 ± 13.1114.9 ± 13.8115.4 ± 9.5116.2 ± 11.8113.7 ± 13.1113.5 ± 12.1109.2 ± 13.0108.4 ± 13.1
Waist-to-hip ratio1.0 ± 0.051.0 ± 0.11.0 ± 0.051.0 ± 0.061.0 ± 0.11.0 ± 0.051.0 ± 0.11.0 ± 0.11.0 ± 0.11.0 ± 0.1
Neck circumference (cm)42.4 ± 3.342.1 ± 3.742.8 ± 3.842.8 ± 3.642.7 ± 3.342.2 ± 3.842.8 ± 3.642.5 ± 4.041.7 ± 4.841.1 ± 4.8
Visceral abdominal fat (L)8.1 ± 1.98.5 ± 2.29.1 ± 3.59.0 ± 3.58.5 ± 3.08.6 ± 2.79.1 ± 2.510.2 ± 2.27.2 ± 2.47.5 ± 3.4
Appetite 0–10 NRS score5.6 ± 1.04.9 ± 1.05.4 ± 1.75.0 ± 1.54.7 ± 1.23.6 ± 1.65.0 ± 2.24.1 ± 1.95.1 ± 1.34.5 ± 1.3
Systolic BP (mmHg)133.4 ± 16.4132.2 ± 13.0135.9 ± 13.4132.8 ± 17.1126.4 ± 11.6134.3 ± 12.8132.7 ± 11.0134.2 ± 14.8137.2 ± 11.9140.4 ± 11.2
Diastolic BP (mmHg)70.1 ± 8.870.6 ± 8.870.6 ± 12.271.0 ± 9.473.2 ± 6.877.5 ± 7.773.5 ± 10.472.2 ± 10.573.0 ± 9.572.3 ± 10.6
Pulse rate (bpm)71.5 ± 17.770.5 ± 15.774.5 ± 12.374.1 ± 12.480.1 ± 12.276.6 ± 8.077.1 ± 12.182.0 ± 15.872.1 ± 10.875.5 ± 7.3
BDI-II score3.8 ± 3.54.6 ± 3.72.8 ± 3.83.3 ± 3.34.5 ± 5.24.7 ± 5.02.8 ± 2.77.9 ± 7.63.5 ± 3.93.5 ± 3.2
AEA0.2 ± 0.10.2 ± 0.050.2 ± 0.10.2 ± 0.10.2 ± 0.10.2 ± 0.10.2 ± 0.040.2 ± 0.10.2 ± 0.10.2 ± 0.1
2-AG5.0 ± 2.94.7 ± 2.94.3 ± 1.713.6 ± 28.66.2 ± 3.15.0 ± 1.53.8 ± 1.53.7 ± 1.75.0 ± 3.35.3 ± 3.4
OEA2.4 ± 1.11.8 ± 0.72.4 ± 1.02.3 ± 0.62.5 ± 0.82.2 ± 0.72.2 ± 0.52.2 ± 0.82.4 ± 0.52.1 ± 0.5
PEA2.7 ± 1.91.8 ± 0.72.7 ± 1.12.5 ± 0.72.5 ± 0.72.4 ± 0.62.5 ± 1.22.6 ± 1.72.9 ± 1.32.0 ± 0.4
  • Data are mean ± SD. Apo B, apolipoprotein B; BP, blood pressure; HOMA2-IR, HOMA2–insulin resistance; NEFA, nonesterified fatty acid; Total-C, total cholesterol; UC, ultracentrifugation.

  • aP < 0.05;

  • bP < 0.01 compared with placebo.